Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 23, 2009
IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease
Kirk A Staschke, Sucai Dong, Joy Saha, et al.
Arthritis Research & Therapy
|
August 4, 2019
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B McInnes, Nicole L Byers, Richard E Higgs, et al.
The Journal of Clinical Investigation
|
April 24, 2008
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice
Matthias Ernst, Meri Najdovska, Dianne Grail, et al.
Molecular Cancer Therapeutics
|
December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity
Robert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
JCI Insight
|
July 10, 2023
A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases
Jeffrey S Boyles, Dorota Sadowski, Scott Potter, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 23, 2009
IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease
Kirk A Staschke, Sucai Dong, Joy Saha, et al.
Arthritis Research & Therapy
|
August 4, 2019
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B McInnes, Nicole L Byers, Richard E Higgs, et al.
The Journal of Clinical Investigation
|
April 24, 2008
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice
Matthias Ernst, Meri Najdovska, Dianne Grail, et al.
Molecular Cancer Therapeutics
|
December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity
Robert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
JCI Insight
|
July 10, 2023
A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases
Jeffrey S Boyles, Dorota Sadowski, Scott Potter, et al.
Page
of 3